Development of liposomal salbutamol sulfate dry powder inhaler formulation

Wen Hua Huang, Zhijun YANG*, Heng Wu, Yuen Fan Wong, Zhongzhen ZHAO, Liang LIU

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)

Abstract

The purpose of our study was to develop a formulation of liposomal salbutamol sulfate (SBS) dry powder inhaler (DPI) for the treatment of asthma. Liposomes of high encapsulation efficiency (more than 80%) were prepared by a vesicular phospholipid gel (VPG) technique. SBS VPG liposomes were subjected to lyophilization using different kinds of cryoprotectants in various mass ratios. Coarse lactose (63-106 μm) in different mass ratios was used as a carrier. Magnesium stearate (0.5%) was added as a lubricator. The dry liposomal powders were then crushed by ball milling and sieved through a 400-mesh sieve to control the mean particle size at about 10 mm. The effects of different kinds of cryoprotectants and the amount of lactose carrier on the fine particle fraction (FPF) of SBS were investigated. The results showed that the developed formulation of liposomal dry powder inhaler was obtained using lactose as a cryoprotectant with a mass ratio of lyophilized powder to carrier lactose at 1 : 5; 0.5% magnesium stearate was used as a lubricator. The value of FPF for SBS was 41.51±2.22% for this formulation. Sustained release of SBS from the VPG liposomes was found in the in vitro release study. The study results offer the promising possibility of localized pulmonary liposomal SBS delivery in the anhydrous state.

Original languageEnglish
Pages (from-to)512-517
Number of pages6
JournalBiological and Pharmaceutical Bulletin
Volume33
Issue number3
DOIs
Publication statusPublished - Mar 2010

Scopus Subject Areas

  • Pharmacology
  • Pharmaceutical Science

User-Defined Keywords

  • Dry powder inhaler
  • Liposome
  • Pulmonary delivery
  • Salbutamol sulfate

Fingerprint

Dive into the research topics of 'Development of liposomal salbutamol sulfate dry powder inhaler formulation'. Together they form a unique fingerprint.

Cite this